EP300 acetylates RUNX3

Stable Identifier
R-HSA-8951966
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

EP300 (p300) histone acetyltransferase acetylates RUNX3 on lysine residues K94 and K171 (Lee et al. 2013), and probably other lysines (Jin et al. 2004). EP300-mediated acetylation of RUNX3 is positively regulated by TGF-beta treatment. Besides increasing the transcriptional activity of RUNX3, EP300-mediated acetylation also increases the half-life of RUNX3, as it interferes with SMURF-mediated ubiquitination and subsequent degradation of RUNX3 (Jin et al. 2004).

Literature References
PubMed ID Title Journal Year
15138260 Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation

Jin, YH, Jeon, EJ, Li, QL, Lee, YH, Choi, JK, Kim, WJ, Lee, KY, Bae, SC

J. Biol. Chem. 2004
24229708 Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma

Lee, YS, Lee, JW, Jang, JW, Chi, XZ, Kim, JH, Li, YH, Kim, MK, Kim, DM, Choi, BS, Kim, EG, Chung, JH, Lee, OJ, Lee, YM, Suh, JW, Chuang, LS, Ito, Y, Bae, SC

Cancer Cell 2013
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
peptide-lysine-N-acetyltransferase activity of RUNX3:CBFB:EP300 [nucleoplasm]
Physical Entity
Activity
This event is regulated
Orthologous Events
Authored
Reviewed
Created